You get enough sleep, yet every day still feels like running on empty. Your energy never quite returns. Coffee no longer sharpens your focus — it just makes your heart race. When you try to do cognitive work, your mind struggles to get going, wrapped in a kind of mental fog that resists clearing. Exercise feels out of reach; even a short walk leaves your joints and muscles feeling stiff, as though your body is held in place by something invisible. Tasks that used to be routine now demand a disproportionate amount of effort. Yet when you see a doctor, standard tests come back normal. You tell yourself it is just the stress of a busy season, or that you simply need to take better care of yourself.
What many people in this situation do not realize is that they may be experiencing a recognized medical condition: Chronic Fatigue Syndrome (CFS), also referred to as Myalgic Encephalomyelitis (ME). CFS is significantly underdiagnosed. In the United States alone, an estimated 3.3 million people are affected, yet fewer than 10% have received a formal diagnosis. Among professionals in high-pressure industries such as information technology, finance, and media, prevalence rates are notably higher. CFS can affect people across all age groups, and women face a substantially higher risk than men. Research also indicates that the risk of developing CFS increases considerably following COVID-19 infection.
One reason CFS goes undetected is its tendency to overlap symptomatically with other conditions, including depression, type 2 diabetes, and rheumatoid arthritis. A practical self-assessment: If you recognize these symptoms, particularly fatigue lasting more than six months that is not relieved by rest, a medical evaluation is recommended.
Part 2: Mitochondrial Dysfunction and the Biology of CFS
What makes chronic fatigue so difficult to overcome, and where does the problem originate? The scientific community has not yet arrived at a definitive answer. Current research suggests that CFS may involve a combination of contributing factors, including chronic low-grade inflammation, disruption of the gut microbiome, viral infection history, and mitochondrial dysfunction. Among these, mitochondrial involvement has received particular attention. Mitochondria are the primary site of cellular energy production and metabolic regulation. They also play critical roles in antioxidant defense, apoptosis regulation, and inflammatory modulation.
Patients with CFS commonly exhibit impaired mitochondrial function — a situation analogous to a factory whose machinery is no longer operating at capacity, resulting in insufficient energy output. This is frequently accompanied by chronic systemic inflammation, a state that continuously taxes the body's resources. NADH (the reduced form of nicotinamide adenine dinucleotide) is recognized as an important mitochondrial nutrient and has been studied in CFS intervention research. NADH is understood to support the body through three core mechanisms:
Part 3: What Clinical Research Has Found
A growing body of clinical studies has examined the potential of NADH in CFS management. While the field is still developing, the accumulated findings offer meaningful signals:
1999 Pilot Study: 31% of Patients Reported Meaningful Improvement
A controlled trial enrolled 26 patients who had experienced chronic fatigue for an average of 7.2 years. Participants received either 10 mg of oral NADH daily or a placebo. In the NADH group, 31% of participants reported reduced fatigue and fewer symptoms, along with measurable improvements in quality of life; the corresponding figure in the placebo group was 8%. Notably, elevated serotonin metabolite levels — present in 50% of patients at baseline — normalized in those receiving NADH.
2004 Comparative Study: Earlier Symptom Improvement with NADH
Thirty-one patients (90% female) were divided into two groups: one received oral NADH starting at 5 mg per day, with the dose increased to 10 mg if initial response was limited; the other received a conventional approach combining nutritional supplementation and psychological support. Both groups were followed for 24 months. The NADH group showed statistically significant symptom score improvements within the first quarter of treatment. While the difference between groups narrowed over the full study period, the NADH group maintained a more consistent improvement trajectory throughout.
2010 Double-Blind Trial: Reduced Anxiety and Improved Stress Response
Eighty-six patients (72 female) participated in a three-month double-blind trial. Half received 20 mg of NADH daily; half received a placebo. Anxiety scores decreased by approximately one point in the NADH group, compared with 0.2 points in the placebo group. A more notable finding emerged from stress testing: peak heart rate following a standardized stress task decreased by 8.1 beats per minute in the NADH group, while increasing by 1.7 beats per minute in the placebo group — suggesting an improvement in the body's capacity to regulate physiological stress responses.
2021 Combination Study: Broader Benefits When Paired with Coenzyme Q10
Two hundred and seven patients were randomized to receive either 20 mg NADH combined with 200 mg coenzyme Q10 and excipients (phosphatidylserine, vitamin C), or excipients alone, for eight weeks. The intervention group demonstrated significant reductions in both cognitive fatigue and overall fatigue scores, along with improvements in sleep duration, sleep efficiency, pain levels, and health-related quality of life. These results are consistent with the established role of coenzyme Q10 and NADH as complementary factors in cellular energy metabolism and antioxidant function.
Part 4: A Comprehensive Approach to Managing Chronic Fatigue
NADH has demonstrated meaningful potential in CFS research, but a well-rounded, evidence-informed approach remains essential for effective management.
CFS currently has no established cure. Management focuses on symptom relief through targeted supplementation and lifestyle-based interventions. If fatigue symptoms have persisted for more than one month, a thorough medical evaluation is recommended. Because CFS symptoms overlap significantly with those of other conditions, professional assessment is important for accurate diagnosis and to avoid delays in appropriate care.
Regarding NADH supplementation specifically, the quality and stability of the product matter considerably. Most commercially available NADH products face challenges in maintaining active-form stability — they may degrade during shelf storage or lose activity upon contact with gastric acid, leaving little biologically available NADH to exert an effect.One example of this innovation is that CELFULL's proprietary Celfavor™ NADH ingredient addresses this through an acid-resistant intestinal sustained-release microsphere technology, which has been granted invention patents in the United States (US11744804B2) and multiple other countries and regions.. This technology is designed to protect NADH through the gastric environment and enable controlled release in the intestine, supporting effective absorption and bioavailability. Celfavor™ NADH is currently incorporated into products distributed across multiple major global markets.
Beyond supplementation, healthy lifestyle practices are a foundational element of CFS management. Prioritizing seven to eight hours of quality sleep allows the body adequate recovery time. Gentle physical activity — such as yoga or walking — pursued gradually and consistently can support overall resilience without triggering post-exertional setbacks. Structuring work and daily life to reduce sustained high-stress periods, and intentionally building in time for rest and recovery, are also important considerations for long-term wellbeing.
References
Forsyth L M, Preuss H G, MacDowell A L, et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome[J]. Annals of Allergy, Asthma & Immunology, 1999, 82(2): 185-191.
Santaella M L, Font I, Disdier O M. Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome[J]. Puerto Rico health sciences journal, 2004, 23(2).
Alegre J, Rosés J M, Javierre C, et al. Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome[J]. Revista clínica española, 2010, 210(6): 284.
Castro-Marrero J, Segundo M J, Lacasa M, et al. Effect of dietary coenzyme Q10 plus NADH supplementation on fatigue perception and health-related quality of life in individuals with myalgic encephalomyelitis/chronic fatigue syndrome: a prospective, randomized, double-blind, placebo-controlled trial[J]. Nutrients, 2021, 13(8): 2658.
Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
